Table 1 Baseline clinical and hematologic characteristics of study patients stratified according to the treatment
From: Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Variables | Ruxo-patients (N = 46) | HU-patients (N = 25) | P |
|---|---|---|---|
Diagnosis, n.(%) | |||
PMF | 23 (50.0) | 19 (76.0) | .050 |
PPV-MF | 16 (35.0) | 2 (8.0) | |
PET-MF | 7 (15.0) | 4 (16.0) | |
Follow-up from the start of treatment, y: median (range) | 3.4 (1.0–7.4) | 2.9 (1.0–11.1) | .981 |
Time from diagnosis to treatment | 1.1 (0.3.6) | 2.8 (0–3.7) | .743 |
Males, n (%) | 22 (48.0) | 15 (60.0) | .232 |
Age, y; median (range) | 63.4 (35.0–81.0) | 66.9 (43.0–88.0) | .087 |
Hemoglobin, g/L; median (range) | 107 (70–140) | 99 (89–109) | .912 |
Leukocytes, x109/L; median (range) | 13.3 (3.0–103.0) | 11.8 (5.8–14.0) | .917 |
Platelets, x109/L; median (range) | 333 (52–750) | 433 (227–1378) | .090 |
Circulating blasts ≥ 1%; n (%) | 12 (26.1) | 7 (28.0) | .993 |
Constitutional symptoms; n (%) | 43 (93.5) | 21 (84.0) | .558 |
Splenomegaly > 10 cm from LCM; n (%) | 35 (76.1) | 10 (40.0) | <.0001 |
Patients with cytogenetic information; N = (% of total) | 42 (91.3) | 21 (84.0) | .202 |
Abnormal cytogenetics | 19 (45.2) | 6 (28.6) | |
Unfavorable karyotype | 4 (9.5) | 2 (9.5) | |
DIPSS | |||
Intermediate-2 | 40 (86.9) | 20 (80.0) | .441 |
High | 6 (13.1) | 5 (20.0) | |
